Eribulin

Generic Name: Eribulin

Brand Names: Halaven, Eribulin Baxter, Mevlyq

Drug Type: Small Molecule

Chemical Formula: C_₄₀H_₅₉NO_₁₁

CAS Number: 253128-41-5

Unique Ingredient Identifier: LR24G6354G

Background: Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for use in the treatment of advanced solid tumors .

Indication: For the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic cancer.

Associated Conditions: Metastatic Liposarcoma, Refractory, metastatic Breast cancer, Unresectable Liposarcoma

Clinical Trials

Study Of Eribulin (E7389) In Patients With Advanced Solid Tumors And Normal Or Reduced Hepatic Function As Per Child-Pugh System

Phase 1

Completed

Conditions: Cancer

Interventions: Drug: E7389

First Posted Date: 2008-06-27

Last Posted Date: 2012-03-27

Lead Sponsor: Eisai Inc.

Target Recruit Count: 18

Registration Number: NCT00706095

Locations: 🇳🇱
Utrecht Medical Centre, Utrecht, Netherlands
🇳🇱
Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands

Eribulin Mesylate and Cisplatin in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: eribulin mesylate
Drug: cisplatin
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2006-12-22

Last Posted Date: 2014-05-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 36

Registration Number: NCT00415324

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸
University of Southern California/Norris Cancer Center, Los Angeles, California, United States
🇺🇸
University of California at Davis Cancer Center, Sacramento, California, United States

and more 1 locations

E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue Sarcoma

Phase 2

Completed

Conditions: Soft Tissue Sarcoma

Interventions: Drug: E7389

First Posted Date: 2006-12-19

Last Posted Date: 2017-04-26

Lead Sponsor: Eisai Inc.

Target Recruit Count: 128

Registration Number: NCT00413192

Eribulin Mesylate and Gemcitabine Hydrochloride in Treating Patients With Metastatic Solid Tumors or Solid Tumors That Cannot be Removed by Surgery

Phase 1

Completed

Conditions: Stage III Ovarian Cancer AJCC v6 and v7
Recurrent Uterine Corpus Carcinoma
Stage III Uterine Corpus Cancer AJCC v7
Recurrent Ovarian Carcinoma
Stage IV Ovarian Cancer AJCC v6 and v7
Stage IV Uterine Corpus Cancer AJCC v7
Adult Solid Neoplasm

Interventions: Drug: Eribulin Mesylate
Drug: Gemcitabine Hydrochloride

First Posted Date: 2006-12-13

Last Posted Date: 2018-10-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 45

Registration Number: NCT00410553

Locations: 🇨🇦
Ottawa Hospital-Civic Campus, Ottawa, Ontario, Canada
🇨🇦
University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada

E7389 in Treating Patients With Recurrent or Progressive Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Stage IV Non-small Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer

Interventions: Drug: eribulin mesylate

First Posted Date: 2006-11-17

Last Posted Date: 2015-01-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 66

Registration Number: NCT00400829

Locations: 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States

E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Physician's Choice
Drug: E7389

First Posted Date: 2006-10-17

Last Posted Date: 2020-01-07

Lead Sponsor: Eisai Inc.

Target Recruit Count: 762

Registration Number: NCT00388726

Locations: 🇺🇸
Montana Cancer Specialists, Missoula, Montana, United States
🇺🇸
Bellflower Satellite, Bellflower, California, United States
🇺🇸
Weill Cornell Breast Cancer Center, New York, New York, United States

and more 118 locations

Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients

Phase 2

Completed

Conditions: Pancreatic Cancer
Adenocarcinoma of the Pancreas
Stage IV Pancreatic Cancer
Stage II Pancreatic Cancer
Recurrent Pancreatic Cancer
Stage III Pancreatic Cancer

Interventions: Drug: eribulin mesylate

First Posted Date: 2006-10-03

Last Posted Date: 2017-10-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 15

Registration Number: NCT00383760

Locations: 🇨🇦
University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada

Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction

Phase 1

Active, not recruiting

Conditions: Advanced Urothelial Carcinoma
Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
Metastatic Urothelial Carcinoma
Recurrent Urothelial Carcinoma
Locally Advanced Urothelial Carcinoma
Stage IV Bladder Urothelial Carcinoma AJCC v7
Unresectable Urothelial Carcinoma

Interventions: Drug: Eribulin Mesylate
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study

First Posted Date: 2006-08-17

Last Posted Date: 2025-02-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 132

Registration Number: NCT00365157

Locations: 🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸
Decatur Memorial Hospital, Decatur, Illinois, United States
🇺🇸
Community Howard Regional Health, Kokomo, Indiana, United States

and more 23 locations

Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Phase 2

Completed

Conditions: Adenocarcinoma of the Prostate
Hormone-refractory Prostate Cancer
Recurrent Prostate Cancer
Stage IV Prostate Cancer

Interventions: Drug: eribulin mesylate

First Posted Date: 2006-06-15

Last Posted Date: 2014-06-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 121

Registration Number: NCT00337077

Locations: 🇺🇸
Sparrow Hospital, Lansing, Michigan, United States
🇺🇸
Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
Virtua West Jersey Hospital Voorhees, Voorhees, New Jersey, United States

and more 143 locations

S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: eribulin mesylate

First Posted Date: 2006-06-15

Last Posted Date: 2015-08-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 42

Registration Number: NCT00337129

Locations: 🇺🇸
Montana Cancer Center at St. Patrick Hospital and Health Sciences Center, Missoula, Montana, United States
🇺🇸
Kalispell Medical Oncology at KRMC, Kalispell, Montana, United States
🇺🇸
UVMC Cancer Care Center at Upper Valley Medical Center, Troy, Ohio, United States

and more 135 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy